Unlocking the secret drivers of deadly pancreatic cancer: New target offers hope for treatment

Researchers identify a super-enhancer-regulated RNA-binding protein cascade that drives the growth of pancreatic ductal adenocarcinoma, a deadly form of pancreatic cancer. The discovery offers a promising new avenue for targeted therapy, potentially sidestepping severe side effects associated with other treatments.

Latest news on BioNTech’s Friday buyout; Unpacking Sarepta’s Duchenne data; Pfizer’s post-Covid plans; Eli Lilly, AstraZeneca’s gene editing deals; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit

November 5, 2023

Deep-learning technology could help scientists to develop personalized immunotherapies and vaccines

Deep-learning technology developed by a team of Johns Hopkins engineers and cancer researchers can accurately predict cancer-related protein fragments that may trigger an immune system

August 9, 2023

GNI Group to form $100M fund with Chinese state-owned enterprises

China’s GNI Group announced on April 18 that it has signed an agreement with Chinese state-owned enterprises and state-invested enterprises to form a $100 million

April 24, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.